To use all functions of this page, please activate cookies in your browser.
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Nizatidine is a histamine H2-receptor antagonist that inhibits stomach acid production, and commonly used in the treatment of peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD). It was developed by Eli Lilly and is marketed under the trade names Tazac and Axid.
Additional recommended knowledge
Main article: H2-receptor antagonist
Certain preparations of nizatadine are now available over the counter in various countries including the United States.
History and development
Nizatidine was developed by Eli Lilly, and was first marketed in 1987. It is considered to be equipotent with ranitidine and differs by the substitution of a thiazole-ring in place of the furan-ring in ranitidine.
Nizatidine proved to be the last new histamine H2-receptor antagonists introduced prior to the advent of proton pump inhibitors.
|This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Nizatidine". A list of authors is available in Wikipedia.|